Ed Arce
Stock Analyst at WestPark Capital
(3.16)
# 1,092
Out of 5,241 analysts
353
Total ratings
47.89%
Success rate
11.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TLPH Talphera | Initiates: Buy | $3 | $0.85 | +253.77% | 7 | Apr 30, 2026 | |
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $24 → $28 | $13.41 | +108.80% | 13 | Sep 30, 2025 | |
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $42.59 | -29.56% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $132 | $1.11 | +11,791.89% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $75 | $8.26 | +807.99% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $7.47 | +703.21% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $1.06 | +607.55% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $5.44 | +138.97% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $2.17 | - | 17 | Apr 2, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $5.71 | +1,125.92% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $28.65 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $240 | $1.92 | +12,400.00% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.15 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $6.90 | +363.77% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $102.19 | -29.54% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $523.69 | -22.66% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $6.23 | -11.72% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $25.00 | +280.00% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $4.24 | +17.92% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $35.44 | +35.44% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $15.28 | -14.92% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $37.32 | -33.01% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.60 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $16.87 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $30.27 | -76.87% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $33.78 | -37.83% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.10 | - | 2 | Feb 15, 2017 |
Talphera
Apr 30, 2026
Initiates: Buy
Price Target: $3
Current: $0.85
Upside: +253.77%
Enanta Pharmaceuticals
Sep 30, 2025
Maintains: Buy
Price Target: $24 → $28
Current: $13.41
Upside: +108.80%
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $42.59
Upside: -29.56%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $132
Current: $1.11
Upside: +11,791.89%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $75
Current: $8.26
Upside: +807.99%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $7.47
Upside: +703.21%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $1.06
Upside: +607.55%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $5.44
Upside: +138.97%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $2.17
Upside: -
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $5.71
Upside: +1,125.92%
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $28.65
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $240
Current: $1.92
Upside: +12,400.00%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.15
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $6.90
Upside: +363.77%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $102.19
Upside: -29.54%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $523.69
Upside: -22.66%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $6.23
Upside: -11.72%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $25.00
Upside: +280.00%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $4.24
Upside: +17.92%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $35.44
Upside: +35.44%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $15.28
Upside: -14.92%
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $37.32
Upside: -33.01%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.60
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $16.87
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $30.27
Upside: -76.87%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $33.78
Upside: -37.83%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $4.10
Upside: -